Translational research in academia and industry

被引：7

作者：

Clackson, Tim ^{[1
]}

机构：

[1] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA

来源：

EXPERIMENTAL BIOLOGY AND MEDICINE | 2006年 / 231卷 / 11期

关键词：

academia; industry; interdisciplinary research; oncology; translational research;

D O I：

10.1177/153537020623101104

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Research that bridges between scientific insights and clinical application is one of the most active and exciting areas of current biomedical activity. Much of this translational work occurs through collaborations between academic and industrial institutions, taking advantage of the respective strengths and resources of the two sectors. However, such collaborations sometimes can be challenging due to differences between the cultures and priorities of the two parties. This article discusses the nature of translational research, with a focus on the academia-industry interface, analyzes the factors important for effective collaborations, and describes specific examples of successful translational research programs.

引用

收藏

页码：1685 / 1689

页数：5

相关论文

共 13 条

[1] Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model [J].

Berger, C ;

Blau, CA ;

Huang, ML ;

Iuliucci, JD ;

Dalgarno, DC ;

Gaschet, J ;

Heimfeld, S ;

Clackson, T ;

Riddell, SR .

BLOOD, 2004, 103 (04) :1261-1269

[2]

CLACKSON T, IN PRESS CHEM BIOL

[3] EGFR inhibitors: what have we learned from the treatment of lung cancer? [J].

Giaccone, G ;

Rodriguez, JA .

NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (11) :554-561

[4] Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers [J].

Iuliucci, JD ;

Oliver, SD ;

Morley, S ;

Ward, C ;

Ward, J ;

Dalgarno, D ;

Clackson, T ;

Berger, HJ .

JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (08) :870-879

[5] Epidermal growth factor receptor mutations in patients with non-small cell lung cancer [J].

Johnson, BE ;

Jänne, PA .

CANCER RESEARCH, 2005, 65 (17) :7525-7529

[6] Cancer drug discovery through collaboration [J].

Lengauer, C ;

Diaz, LA ;

Saha, S .

NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (05) :375-380

[7] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[8] Pharmacologically regulated in vivo selection in a large animal [J].

Neff, T ;

Horn, PA ;

Valli, VE ;

Gown, AM ;

Wardwell, S ;

Wood, BL ;

von Kalle, C ;

Schmidt, M ;

Peterson, LJ ;

Morris, JC ;

Richard, RE ;

Clackson, T ;

Kiem, HP ;

Blau, CA .

BLOOD, 2002, 100 (06) :2026-2031

[9] EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].

Paez, JG ;

Jänne, PA ;

Lee, JC ;

Tracy, S ;

Greulich, H ;

Gabriel, S ;

Herman, P ;

Kaye, FJ ;

Lindeman, N ;

Boggon, TJ ;

Naoki, K ;

Sasaki, H ;

Fujii, Y ;

Eck, MJ ;

Sellers, WR ;

Johnson, BE ;

Meyerson, M .

SCIENCE, 2004, 304 (5676) :1497-1500

[10] Long-term pharmacologically regulated expression of erythropoietin in,primates following AAV-mediated gene transfer [J].

Rivera, VM ;

Gao, GP ;

Grant, RL ;

Schnell, MA ;

Zoltick, PW ;

Rozamus, LW ;

Clackson, T ;

Wilson, JM .

BLOOD, 2005, 105 (04) :1424-1430